The new year of 2021 has dawned. Due to the world-wide spread of COVID-19 infection from last year, we are experiencing unprecedented challenges in developing and adapting to contactless meetings in many aspects of social, economic, and cultural areas. We all earnestly hope this unwanted affliction will end soon. And I wish you all the best.
This year is truly meaningful year to mark the 50th anniversary since the Korean Society of Pharmaceutical Sciences and Technology (KSPST) was founded in 1971. To realize the great objectives of both “persistent development of pharmaceutical sciences” and “contribution to human welfare”, KSPST was established with its detailed goals of globalizing the Society, promoting cooperation between industry and academia, developing science-based pharmaceutical formulation technology, strengthening academic activities, and exchanging information with oversea academic societies.
Thanks to the enthusiasm and efforts of the former presidents and members, KSPST has continuously been playing key roles in the development of specialized pharmaceutical products, academic research, and policy making. Furthermore, it has grown into one of the leading academic societies both at home and abroad by hosting international symposiums such as 2013 AFPS, 2014 FIP, and 2019 AASP.
Korea has laid the foundation for a competitive system with advanced pharmaceutical countries and strengthened its international position greatly by affiliating the PIC/S in 2014 and obtaining the qualification as a regular member of the ICH in 2016. All the achievement like these have been possible through constant participation and dedication of our members, and from the warm interest, encouragement and generous support of many pharmaceutical industries.
In recent years, traditional major industries are striving to take the initiative of new businesses in high-tech industries such as autonomous vehicles and artificial intelligence (AI) as global competition in these areas has been intensifying in the past few years. In addition, the competition for biopharmaceutical development, including the development of vaccines and treatment agents, is now becoming even more intense due to the ongoing pandemic. The proportion of the global pharmaceutical market (in terms of both sales and number of global pharmaceutical items) in the fields of biological products, genetically modified drugs, cell and gene therapy products, and biosimilars is rapidly increasing. On the other hand, this indicates that the proportion of classic synthetic drugs in the market is on the decline.
According to reports, Korea's exports are concentrated on specific items such as semiconductors with low employment effect, and automobile with high job-inducing effects. However, automobile exports are continuously decreasing, and new businesses such as medicines/bio-industry that have high added value and job-inducing effects are still in a state of import specialization compared to developed countries. In addition, there were cases where drug products were canceled due to carcinogens being present in the drug substance, but this has raised the need to strengthen international competitiveness through safe use of generic drugs and improvement of drug quality.
Therefore, it would be very meaningful for our Society to develop and transform into a central society for contributing to the growth of the pharmaceutical and bio-industries, thus finally bringing increase of gross national product, creation of job, and social problem solving. We will contribute to the role of a central body for information exchange in the pharmaceutical and biopharmaceutical industry, academic research, government policy proposal, and mutual cooperation and exchange between industry, academia, government, and research institutes.
The journal of Pharmaceutical Investigation (JPI), an official journal of KSPST, plays a pivotal role in the academic information exchange of our society. Thanks to the support of board editors and members, its Impact Factor (IF) has increased from 1.34 in 2015 to 3.22 in 2018. This already demonstrates the infinite potential to grow into an international journal. Now is the time to make continuous efforts for entry into SCIE, our ultimate and long-awaited goal. We ask for your continued interest and cooperation for the growth of this journal.
We respect the opinions of members and the former presidents, and will work hard to make the society members happier based on the spirit of communication, harmony, and participation.
Thank you again to the members of the industry, academia, government, and research institutes for their efforts and sponsorship to develop the society. The 2021 executive officers will do our best for the continuous development of the society. We look forward to your voluntary participation and active cooperation. Thank you very much.
Oh-Seung Kwon, Ph.D.
President, The Korean Society of Pharmaceutical and Technology